Bone metabolism in inflammatory bowel diseases 1

Česká verzia

Authors: Tomáš Kupka; Pavel Svoboda; Martina Bojková; Martin Blaho; Adam Vašura ; Vladimír Hrabovský; Petr Dítě
Authors place of work: Oddělení gastroenterologie Interní klinika LF OU a FN Ostrava
Published in the journal: Vnitř Lék 2020; 66(7): 3-7
Category:

Summary

Inflammatory Bowel Disease encompasses Crohn’s Disease, which is capable of affecting the entire GI tract, although usually favors the ileocolonic and perianal areas, and Ulcerative Colitis, which is limited to the colon. The pathophysiology is not fully understood but is thought to be caused by a complex interplay among gut microbiota, dysregulation of the host’s immune system, genetic susceptibility and environmental factors. Osteopenia and osteoporosis are considered to be extraintestinal manifestations of inflammatory bowel disease. Osteoporosis is usually diagnosed by dual-energy X-ray absortiometry. Early interventions to treat active CD and preventative treatment strategies to reduce excessive bone loss might prevent long term consequences of bone loss, including fractures. The immune response in IBD includes increased production of variety of proinflammatory cytokines such as IL1β, TNFα, IL6 a IL1 from T cells and macrophages. These have both direct and indirect effects on bone turnover. Vitamin D is vital in mantenance of bone strenght, mineralisation and fracture prevention. Vitamin D’s physiological importance has also been implicated in a number of inflammatory diseases, mainly asthma, atherosclerosis and autoimmune disease.

Keywords:

bone mineral density (BDM) – inflammatory bowel disease – osteoporosis – vitamin D

Zdroje

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental issues. Gastroenterology 2004; 126: 1504–1517.

2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.

3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307–317.

4. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2–6.

5. Loftus jr. EV. Osteoporosis and Inflammatory Bowel Disease. Healio Rheumatology 2017. Availalble from WWW: < https://www.healio.com/rheumatology/osteoarthritis-and-bone-disorders/news/print/healio-rheumatology/%7B9391f09f-6b83-40dc-a913-080747d434e0%7D/osteoporosis-and-inflammatory-bowel-disease>

6. Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenter Hepatol 2010; 6: 506–517.

7. Bischoff SC, Herrmann A, Göke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157–1163.

8. Bernstein CN, Benchimol EI, Bitton A, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. J Can Assoc Gastroenterol 2019; 2: (Suppl. 1): S73–S80.

9. Sugimoto K, Ikeya K, et al. An increased serum N-terminal telopeptide of type I collagen, a biochemical marker of increased bone resorption, is association with infliximab therapy in patients with Crohn’s disease. Dig Dis Sci 2016; 61: 99–106

10. Metzger CE, Narayanan A, Zawieja DC, et al. Inflammatory Bowel Disease in a Rodent Model Alters Osteocyte Protein Levels Controlling Bone Turnover. J Bone Miner Res 2017; 32: 802–813.

11. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008; 57: 684–694.

12. Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int 2012; 91: 356–363.

13. Hidalgo DF, Boonpheng B, Phemister J, et al. Inflammatory Bowel Disease and Risk of Osteoporotic Fractures: A Meta-Analysis. Cureus 2019; 11: e5810.

14. Lewiecki EM, Borges JL. Bone density testing in clinical practice. Arq Bras Endocrinol Metabol 2006; 50: 586–595.

15. NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.

16. Couttenye MM, D’Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transpl 1996; 11: 1065–1072.

17. Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000; 15: 594-598.

18. Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn’s disease? Lancet 2001; 357: 1995–1996.

19. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn’s disease patients. Inflamm Bowel Dis 2009; 15: 1656–1662.

20. Leichtmann GA, Bengoa JM, Bolt MJ, et al. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr 1991; 54: 548–552.

21. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410–415.

22. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228–233.

23. van Bodegraven AA, et al. Treatment of bone loss in osteopenic patients with Crohn’s disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut 2014; 63: 1424–1430.

24. Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2014; 12: 32–44.

25. Redlich K, Smolen J. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11: 234–250.

26. Katz S, Weinerman S. The elderly inflammatory bowel disease patient and osteoporosis. Aging Health 2012; 8: 31–42.

27. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359–367.

28. Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: an unusual presentation of childhood Crohn’s disease. J Clin Endocrinol Metab 2000; 85: 2122–2126.

29. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956–3964.

30. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275: 4858–4864.

31. Kaji K, Katogi R, Azuma Y, et al. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res 2001; 16: 1593–1599.

32. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986; 319: 516–518.

33. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134: 222–231.

34. Fernandez-Martin JL, Kurian S, Farmer P, et al. Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors. Mol Cell Endocrinol 1998; 141: 65–72.

35. Horwood NJ, Elliott J, Martin TJ, et al. IL-12 alone and in synergy with IL-18 inhibits osteoclasts formation in vitro. J Immunol 2001; 166: 4915–4921.

36. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn’s disease. J Immunol 1999; 163: 143–147.

37. Quinn JM, Itoh K, Udagawa N, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001; 16: 1787–1794.

38. Tauseef A, Lam D, Bronze M, et al. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122: 599–604.

39. Łodyga M, Eder P, Bartnik W, et al. Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Prz Gastroenterol 2012; 7: 317–338.

40. Krela-Kaźmierczak I, Wysocka E, Szymczak A, et al. Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn’s disease. Prz Gastroenterol 2016; 11: 30–34.

41. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54: 479–487.

42. Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9: 251–257.

43. Geginat J, Larghi P, Paroni M, et al. The light and the dark sides of Interleukin – 10 in immune – mediated diseases and cancer. Cytokine Growth Factor Rev 2016; 30: 87–93.

44. Evans KE, Fox SW. Interleukin – 10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 2007; 8: 4.

45. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26: 229–238.

46. Baek K, Hwang HR, Park HJ, et al. TNF-α upregulates sclerostin expression in obese mice fed a high – fat diet. Cell Physiol 2014; 229: 640–650.

47. Ghishan FK, Kiela P. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011; 300: G191-G201.

48. DiStefano M, Veneto G, Malserervis S, et al. Lactose malabsorption and intolerance and peak bone mass. Gastroenterology 2002; 122: 1793–1799.

49. Razzaque MS. The FGF23-Klotho axis endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611–619.

50. Booth SL. Roles for vitamin K beyond coagulation. Ann Rev Nutr 2009; 28: 88–110.

51. Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011; 27: 1023–1028.

52. Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 2009; 13: 1–134.

53. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010; 123: 877–884.

54. Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 2007; 32: 733–757.

55. Canalis E, Mazziotti G, Giustina A, et al. Glucorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319–1328.

56. Tan B, Li P, Lv H, et al. Vitamin D and BMD in Chinese IBD patients. Journal of Digestive Diseases 2014; 15: 116–123.

57. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904.

58. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209–1218.

59. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25: 786–795.

60. Sgambato D, Gimigliano F, De Musis C, et al. Bone alterations in inflammatory bowel diseases. World J Clin Cases 2019; 7: 1908–1925.